HCV/HBV infection in Italian patients (pts) with solid tumor candidates for chemotherapy (CT).
2014; Lippincott Williams & Wilkins; Volume: 32; Issue: 15_suppl Linguagem: Inglês
10.1200/jco.2014.32.15_suppl.e12521
ISSN1527-7755
AutoresFabiola Lorena Rojas Llimpe, Francesca Di Fabio, Claudia Degli Esposti, P. Di Tullio, V. Mutri, Daniela Adua, S. Giaquinta, Francesca Sperandi, Bruna Angelelli, Barbara Melotti, Marco Montagnani, Carmine Pinto,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
Resumoe12521 Background: There are few studies dealing with the prevalence of chronic infection by HBV or HCV in Italian pts candidated to CT for solid tumors and on the episodes of hepatitis reactivation during the CT. Methods: Pts referred to S.Orsola-Malpighi Hospital Medical Oncology Unit undergo to blood tests (BT) that include a screening for HBV and HCV infection by testing the positivity for HbsAg and anti-HCV. We examined the records of 564 consecutive new pts from January to December 2012. Pts who performed at least 1 BT were considered elegible: 479/564 (84.9%). Results: Pts screened: 435(90.8%) HbsAg, 397(82.9%) anti-HCV and 397 (82.9%) for both. 24 pts were found positive: 9 (1.9%) HBsAg+, 14 (3.5%) anti-HCV+, 1 (0.3%) HBsAg+/anti-HCV+. Males 16 (66.7%). Primary tumors: 9 (37.5%) liver, 4 (16.7%) lung, 3 (12.5%) head-neck, 3 (12.5%) colon, 2 (8.3%) bladder, 1 (4.2%) anus, 1 (4.2%) breast, 1 (4.2%) gastric, 1 (4.2%) skin. 3/24 pts (12.5%) with abnormal liver function tests at baseline were not treated. 10/24 (41.7%) pts had received previous therapy for hepatitis: 3 (1 HBsAg+, 3 anti-HCV+) interferon(IFN); 5 (anti-HCV+) IFN + ribavirin (rib); 2 (HBsAg+) lamivudine (lam). 3/24 pts were still receiving therapy for hepatitis: 2 with lam (maintained during CT), 1 IFN/rib (suspended at time of CT). After hepatological evaluation 3 pts started prophylactic lam, 5 not received prophylaxis. 17/24 pts (10 HBsAg+, 7 anti-HCV+) underwent CT/oral therapy: 12 platinum compounds, 1 vinorelbine, 1 Nigro regimen, 1 anastrozole, 1 gefitinib, 1 sorafenib. 4/24 pts anti-HCV+ underwent locoregional treatment: 3 ittrium, 1 TACE. 9 (42.86%) pts completed antineoplastic treatment as planned (5HBsAg+, 4 anti-HCV+). 5/24 (23.81%) pts stopped CT because of rapid progression of the neoplastic disease (2 HBsAg+, 2 anti-HCV+, 1 HBsAg+/anti-HCV+). 3 (14.29%) pts had several suspensions of CT until the definitive interruption: 2 neutropenia (1 HBsAg+, 1 anti-HCV+); 1 hypertransaminasemia (HBsAg+). Conclusions: In our series the prevalence of HbsAg and anti-HCV positivity was: 1.9% and 3.5% respectively. CT is feasible in pts with chronic HBV/HCV infection. None of our pts showed viral reactivation although not all received prophylaxis during CT.
Referência(s)